Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07K-016/00
A61K-039/285
A61K-039/00
C07K-016/30
A61K-035/76
A61K-035/761
A61K-035/763
A61K-035/768
A61K-035/26
A61K-039/12
A61K-039/125
A61K-039/145
A61K-039/165
A61K-039/17
A61K-039/205
A61K-039/235
A61K-039/245
A61K-039/395
A61K-045/06
C07K-016/18
C12N-007/00
G01N-033/574
출원번호
US-0978113
(2012-01-04)
등록번호
US-9919047
(2018-03-20)
국제출원번호
PCT/US2012/020173
(2012-01-04)
§371/§102 date
20141024
(20141024)
국제공개번호
WO2012/094386
(2012-07-12)
발명자
/ 주소
Kirn, David
Bell, John
Breitbach, Caroline
Moon, Anne
Hwang, Tae-Ho
Lee, Yu Kyoung
Kim, Mi-kyung
출원인 / 주소
SILLAJEN, INC.
대리인 / 주소
Polsinelli PC
인용정보
피인용 횟수 :
0인용 특허 :
131
초록▼
The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administ
The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
대표청구항▼
1. A pharmaceutical composition comprising a therapeutically effective amount of polyclonal complement dependent cytotoxic (CDC)-response producing antibodies specific to multiple tumor cell antigens in an animal and a pharmaceutically acceptable carrier and/or diluent, wherein said composition is p
1. A pharmaceutical composition comprising a therapeutically effective amount of polyclonal complement dependent cytotoxic (CDC)-response producing antibodies specific to multiple tumor cell antigens in an animal and a pharmaceutically acceptable carrier and/or diluent, wherein said composition is produced by a method comprising (a) administering to an animal having a tumor an amount of a composition comprising a replication competent oncolytic vaccinia virus effective to induce polyclonal antibodies in said animal that mediate a CDC response specific to said tumor cell antigens and thereafter (b) obtaining a blood or serum sample from the animal containing said CDC-response producing antibodies and/or B cells producing said antibodies (c) confirming the presence of said antibodies and/or B cells producing said antibodies in said blood or serum sample and (d) isolating CDC-response producing antibodies from said blood or serum, expanding said CDC-response producing antibodies ex vivo or producing CDC-response producing antibodies from said B cells and formulating into a composition, wherein the composition comprises polyclonal antibodies that recognize multiple tumor cell antigens selected from the group consisting of RecQ protein-like (DNA helicase Q1-like) (RECQL); leptin receptor (LEPR); ERBB receptor feedback inhibitor 1 (ERRFI1); lysosomal protein transmembrane 4 alpha (LAPTM4A); and RAB1B, RAS oncogene family (RAB1B). 2. The composition of claim 1 wherein said oncolytic virus is JX-594. 3. The composition of claim 1 wherein said oncolytic virus comprises a transgene. 4. The composition of claim 3 wherein said heterologous nucleic acid sequence encodes GM-CSF, cytosine deaminase, carboxyl esterase, sodium iodide symporter (NIS), or stomatostatin receptor. 5. The composition of claim 1 wherein said tumor is selected from the group consisting of astrocytoma, oligodendroglioma, meningioma, neurofibroma, glioblastoma, ependymoma, Schwannoma, neurofibrosarcoma, neuroblastoma, pituitary adenoma, medulloblastoma, head and neck cancer, melanoma, prostate carcinoma, renal cell carcinoma, pancreatic cancer, breast cancer, lung cancer, colon cancer, gastric cancer, bladder cancer, liver cancer, bone cancer, rectal cancer, ovarian cancer, sarcoma, gastric cancer, esophageal cancer, cervical cancer, fibrosarcoma, squamous cell carcinoma, neurectodermal, thyroid tumor, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hepatoma, mesothelioma, epidermoid carcinoma, and tumorigenic diseases of the blood. 6. The composition of claim 1 isolated according to a method comprising isolating CDC-response producing antibodies from said blood or serum. 7. The composition of claim 1 wherein a serum sample is obtained from said subject. 8. A method of inhibiting the growth of or killing a cancer cell comprising contacting said cancer cell with an amount of a composition of claim 1 effective to mediate a CDC-response specific to said cancer cell. 9. The method of claim 8 wherein said contacting comprises contacting cancer cells in vitro with said composition. 10. The method of claim 8 wherein said contacting comprises infusing a subject having cancer with a composition comprising harvested antibodies, harvested B cells, antibodies produced by said harvested B cells or a combination thereof. 11. The method of claim 8 wherein said cancer cell is in vivo in a subject and said contacting comprising administering a medicament comprising said composition. 12. A method of treating a cancer subject comprising administering to said subject an amount of a composition of claim 1 effective to mediate a CDC response to specific to said cancer. 13. The method of claim 12 wherein said composition is autologous to said patient and is isolated from the said cancer patient and reinfused into said cancer patient. 14. The method of claim 12 wherein said composition heterologous to said cancer patient and is isolated from a cancer patient that is different from the cancer patient being treated with said composition. 15. The method of claim 12 wherein said subject is treated with a further anticancer therapeutic agent. 16. The method of claim 12 wherein said cancer subject has as solid tumor and said composition is administered intratumorally, intravenously, intraperitoneally or a combination thereof. 17. The method of claim 16 wherein said cancer subject has a solid tumor that is resected prior to, concurrently or subsequent to administering said composition of claim 6. 18. The method of claim 12 wherein said cancer subject has a solid tumor and said composition reduces the size of the tumor. 19. The method of claim 12 wherein said cancer subject has a solid tumor and said administration reduces metastatic spread of said solid tumor. 20. The method of claim 12 wherein said cancer is selected from the group consisting of astrocytoma, oligodendroglioma, meningioma, neurofibroma, glioblastoma, ependymoma, Schwannoma, neurofibrosarcoma, neuroblastoma, pituitary adenoma, medulloblastoma, head and neck cancer, melanoma, prostate carcinoma, renal cell carcinoma, pancreatic cancer, breast cancer, lung cancer, colon cancer, gastric cancer, bladder cancer, liver cancer, bone cancer, rectal cancer, ovarian cancer, sarcoma, gastric cancer, esophageal cancer, cervical cancer, fibrosarcoma, squamous cell carcinoma, neurectodermal, thyroid tumor, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hepatoma, mesothelioma, epidermoid carcinoma, and tumorigenic diseases of the blood. 21. The method of claim 18, wherein the tumor is hepatocellular carcinoma. 22. The composition according to claim 1, wherein the animal is a human. 23. The method of claim 15, wherein the further anti-cancer therapeutic agent is sorafenib or sunitinib. 24. A pharmaceutical composition comprising a therapeutically effective amount of polyclonal complement dependent cytotoxic (CDC)-response producing antibodies specific to multiple tumor cell antigens in an animal and a pharmaceutically acceptable carrier and/or diluent, wherein said composition is produced by a method comprising (a) administering to an animal having a tumor an amount of a composition comprising a replication competent oncolytic vaccinia virus effective to induce polyclonal antibodies in said animal that mediate a CDC response specific to said tumor cell antigens and thereafter (b) obtaining a blood or serum sample from the animal containing said CDC-response producing antibodies and/or B cells producing said antibodies (c) confirming the presence of said antibodies and/or B cells producing said antibodies in said blood or serum sample and (d) isolating CDC-response producing antibodies from said blood or serum, expanding said CDC-response producing antibodies ex vivo or producing CDC-response producing antibodies from said B cells and formulating into a composition, wherein the composition comprises polyclonal antibodies that recognize multiple tumor cell antigens selected from the group consisting of RecQ protein-like (DNA helicase Q1-like) (RECQL); leptin receptor (LEPR); ERBB receptor feedback inhibitor 1 (ERRFI1); lysosomal protein transmembrane 4 alpha (LAPTM4A); RAB1B, RAS oncogene family (RAB1B); CD24; homo sapiens thymosin beta 4, X-linked (TMSB4X); homo sapiens S100 calcium binding protein A6 (S100A6); homo sapiens adenosine A2 receptor (ADORA2B); chromosome 16 open reading frame 61 (C16orf61); ROD1 regulator of differentiation 1 (ROD1); NAD-dependent deacetylase sirtuin-2 (SIR2L); tubulin alpha 1c (TUBA1C); ATPase inhibitory factor 1 (ATPIF1); stromal antigen 2 (STAG2); and nuclear casein kinase and cyclin-dependent substrate1 (NUCKS1).
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (131)
Kumar Rajan, Amplification method for a polynucleotide.
Lilley Stephen John,GBX ; Taylor Hugh Francis,GBX ; Theobald David Reginald,GBX ; Carlson Craig J. ; Rosen David I. ; Johnson Thomas R., Coupling device for medical injection system.
Glazer Alexander N. ; Mathies Richard A. ; Hung Su-Chun ; Ju Jingyue, Cyanine dyes with high-absorbance cross section as donor chromophores in energy transfer labels.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Delivery of exogenous DNA sequences in a mammal.
Babon Jeff,AUX ; Youil Rima,AUX ; Stoerker Jay ; Huff Anne ; Cotton Richard G. H.,AUX, Detection of mismatches by resolvase cleavage using a magnetic bead support.
Brow Mary Ann D. ; Hall Jeff Steven Grotelueschen ; Lyamichev Victor ; Olive David Michael ; Prudent James Robert, Detection of nucleic acid sequences by invader-directed cleavage.
Nadeau James G. ; Pitner J. Bruce ; Schram James L. ; Linn C. Preston ; Vonk Glenn P. ; Walker G. Terrance, Detection of nucleic acids by fluorescence quenching.
Nadeau James G. ; Pitner J. Bruce ; Schram James L. ; Linn C. Preston ; Vonk Glenn P. ; Walker G. Terrance, Detection of nucleic acids by fluorescence quenching.
Whiteley Norman M. (San Carlos CA) Hunkapiller Michael W. (San Carlos CA) Glazer Alexander N. (Orinda CA), Detection of specific sequences in nucleic acids.
Sedlacek Hans-Harald,DEX ; Bosslet Klaus,DEX ; Muller Rolf,DEX, Gene therapy of tumors with an endothelial cell-specific, cell cycle-dependent active compound.
Krzyzek Richard A. (Edina MN) Laursen Cheryl R. M. (St. Paul MN) Anderson Paul C. (Minneapolis MN), Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Induction of a protective immune response in a mammal by injecting a DNA sequence.
Nelson Norman Charles ; Woodhead James Stuart,GBX ; Weeks Ian,GBX ; Cheikh Azzouz Ben, Labeled hybridization assay probes useful for the detection and quantification of multiple nucleic acid sequences.
Cleuziat Philippe,FRX ; Guillou-Bonnici Francoise,FRX ; Mallet Francois,FRX ; Levasseur Pierre,FRX, Method for nucleic acid amplification by transcription using displacement, and reagents and kit therefor.
Mirzabekov Andrei Darievich,RUX ; Lysov Yuri Petrovich,RUX ; Dubley Svetlana A.,RUX, Method for performing site-specific affinity fractionation for use in DNA sequencing.
Michael J. Mastrangelo ; Edmund C. Lattime ; David Berd ; Laurence C. Eisenlohr, Method of inducing an immune response using vaccinia virus recombinants.
Mastrangelo Michael J. ; Lattime Edmund C. ; Berd David ; Eisenlohr Laurence C., Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Wu Linxian ; Coombs Jana ; Malmstrom Sharon L. ; Glass Michael J., Methods and apparatus for preparing, amplifying, and discriminating multiple analytes.
Adams Thomas R. (No. Stonington CT) Chambers Sheryl A. (Groton CT) Daines Richard J. (Ledyard CT) Gordon-Kamm William J. (Stonington CT) Kausch Albert P. (Stonington CT) Lemaux Peggy G. (Mystic CT) M, Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof.
Heller Michael James ; O'Connell James Patrick ; Juncosa Robert David ; Sosnowski Ronald George ; Jackson Thomas Ratcliffe, Methods for hybridization analysis utilizing electrically controlled hybridization.
Chang Yin-Fu (Carrboro NC) Wong James R. (Milpitas CA) Itano Andrea (Berkley CA) Mejza Stephen J. (Union City CA) Walker Leslie (Littleton CO), Methods for stable transformation of wheat.
Sousa Rui ; Jendrisak Jerome J., Methods for using mutant RNA polymerases with reduced discrimination between non-canonical and canonical nucleoside trip.
Mirzabekov Andrei Darievich,RUX ; Lysov Yuri Petrovich,RUX ; Shick Valentine Vladimirovich ; Dubiley Svetlana Alekseevna,RUX, Microchip method for the enrichment of specific DNA sequences.
Paoletti Enzo ; Perkus Marion E. ; Taylor Jill ; Tartaglia James ; Norton Elizabeth K. ; Riviere Michel,FRX ; de Taisne Charles,FRX ; Limbach Keith J. ; Johnson Gerard P. ; Pincus Steven E. ; Cox Wil, Modified recombinant vaccinia virus and expression vectors thereof.
Hase Tetsu,JPX ; Masubuchi Harumi,JPX, Nucleic acid detection by repetitive synthesis and degradation of a nucleotide on a nuclease resistant oligonucleotide.
Urdea Michael S. ; Horn Thomas ; Chang Chu-An ; Warner Brian ; Fultz Timothy J., Nucleic acid hybridization assays employing large comb-type branched polynucleotides.
Hollis Mark A. ; Ehrlich Daniel J. ; Murphy R. Allen ; Kosicki Bernard B. ; Rathman Dennis D. ; Mathews Richard H. ; Burke Barry E. ; Eggers Mitch D. ; Hogan Michael E. ; Varma Rajender Singh, Optical and electrical methods and apparatus for molecule detection.
Mullis Kary B. (La Jolla CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or cloning nucleic acid sequences.
Mullis Kary B. (Kensington CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or-cloning nucleic acid sequences.
Schilperoort Robbert A. (Vincent van Goghlaan 40 2343 RP Oegstgeest NLX) Krens Frans A. (Scheveningen NLX) Wullems George J. (Warmond NLX), Process for the in-vitro transformation of plant protoplasts with plasmid DNA.
Shuler Charles P. (Westlake Village CA) Kedes Lawrence H. (Los Angeles CA) Prigozy Theodore I. (Los Angeles CA), Producing a protein in a mammal by injection of a DNA-sequence into the tongue.
Feinstone Stephen M. (3021 Cathedral Ave. ; NW. Washington DC 20008) Wychowski Czeslaw (10500 Montrose Ave. #2 Bethesda MD 20814) Silver Jonathan E. (7516 Arrowood Rd. Bethesda MD 20817) Emerson Suza, Techniques for producing site-directed mutagenesis of cloned DNA.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.